InvestorsHub Logo
Followers 13
Posts 697
Boards Moderated 0
Alias Born 01/12/2013

Re: JPetroInc post# 96183

Sunday, 03/02/2014 7:17:37 PM

Sunday, March 02, 2014 7:17:37 PM

Post# of 130503
JP: I believe the MedGenesis Study results will be out in a reasonable timeframe or within a month or two. JN said this reality could affect AMBS (if positive).

MedGenesis Therapeutix raises $5.0 million in equity financing to support the Phase II development of GDNF in Parkinson's Disease

Victoria, British Columbia, January 10, 2012 - MedGenesis Therapeutix Inc, a privately held biotechnology company focused on the development of definitive treatments for neurologic disease, announced today that it has raised $5.0 million to support the phase II clinical development of glial cell derived neurotrophic factor protein (GDNF) in Parkinson's disease. GDNF is a naturally-occurring growth factor capable of protecting and promoting the survival of dopamine producing nerve cells.